Prosecution Insights
Last updated: October 02, 2026

Examiner: SCHULTZHAUS, JANNA NICOLE

Tech Center 1700 • Art Units: 1631 1671 1682 1685 1796

This examiner grants 35% of resolved cases

Analysis

Janna Nicole Schultzhaus is an examiner in Tech Center 1700 and Art Unit 1631. She has 94 resolved cases. The allowance rate for these cases is 35.1 percent. This 35.1 percent rate indicates the proportion of applications that result in a patent grant. Practitioners can use this 94-case history to understand the examiner's general tendencies in Art Unit 1631.

The interview lift is 37.0 percent. This 37.0 percent figure represents the difference in allowance probability when an interview is conducted. A positive value like 37.0 percent indicates that interviews are associated with a higher likelihood of allowance. This suggests that requesting an interview is an effective strategy for this docket.

The median days to allowance is 1724. This 1724-day duration is the middle value for the time from filing to grant. For applicants, this 1724-day median is a key metric for planning the prosecution timeline. By combining the 35.1 percent allowance rate with the 1724-day median, practitioners can develop a data-grounded strategy for their applications.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

35.1%
Allow Rate
-29.9% vs TC avg
128
Total Applications
+37.0%
Interview Lift
1724
Avg Prosecution Days
Based on 94 resolved cases, 2023–2026

Rejection Statute Breakdown

32.5%
§101 Eligibility
8.1%
§102 Novelty
24.6%
§103 Obviousness
26.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18531920 METHODS FOR DETECTION OF FUSIONS USING COMPRESSED MOLECULAR TAGGED NUCLEIC ACID SEQUENCE DATA Non-Final OA LIFE TECHNOLOGIES CORPORATION
18143828 METHODS FOR DEEP ARTIFICIAL NEURAL NETWORKS FOR SIGNAL ERROR CORRECTION Non-Final OA LIFE TECHNOLOGIES CORPORATION
18136072 QUANTIFYING THE RESPONSE-SPECIFICITY OF MONONUCLEAR CELLS AND USES THEREOF Non-Final OA The Regents of the University of California
18428160 INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD, NON-TRANSITORY COMPUTER-READABLE STORAGE MEDIUM AND SORTING SYSTEM Final Rejection Sony Group Corporation
17635997 INFORMATION PROCESSING DEVICE, DISPLAY METHOD, PROGRAM, AND INFORMATION PROCESSING SYSTEM Non-Final OA Sony Group Corporation
17876493 Designing Chemical or Genetic Perturbations using Artificial Intelligence Non-Final OA REGENTS OF THE UNIVERSITY OF MICHIGAN
17694679 Automated Interpretation of Protein Capillary Electrophoresis Data Final Rejection WASHINGTON UNIVERSITY
17793968 METHODS OF FUNCTIONALLY SCREENING BIOLOGICAL SEQUENCE FRAGMENTS Final Rejection Massachusetts Institute of Technology
17963532 SYSTEMS AND METHODS FOR PREDICTING THE TASTE OF A USER Non-Final OA KPN INNOVATIONS, LLC.
18549621 WORKFLOW TO ASSIGN PUTATIVE SOURCE TO DE NOVO PEPTIDE SEQUENCE Non-Final OA REGENERON PHARMACEUTICALS, INC.
18021413 CANCER TEST METHOD USING METABOLITE LIST Non-Final OA HITACHI HIGH-TECH CORPORATION
18049498 ASSOCIATIVE PROCESSING MEMORY SEQUENCE ALIGNMENT Non-Final OA MICRON TECHNOLOGY, INC.
18049506 ASSOCIATIVE PROCESSING MEMORY SEQUENCE ALIGNMENT Non-Final OA MICRON TECHNOLOGY, INC.
17779959 APPARATUS AND METHOD FOR DYNAMIC VISUALIZING AND ANALYZING MICROBIOME IN ANIMALS Final Rejection DSM IP Assets B.V.
17848169 METHODS AND SYSTEMS FOR ASSAY REFINEMENT Final Rejection Nautilus Subsidiary, Inc.
18544216 SYSTEMS AND METHODS FOR DATA COMMUNICATION, STORAGE, AND ANALYSIS USING REFERENCE MOTIFS Final Rejection Intertrust Technologies Corporation
18231793 METHOD FOR PREDICTION OF FUTURE CARDIOVASCULAR DISEASE RISK VIA ANALYSIS OF IgG GLYCOME Non-Final OA The Brigham and Women’s Hospital, Inc.
17356146 IN VIVO DETECTION OF EGFR MUTATION IN GLIOBLASTOMA VIA MRI SIGNATURE CONSISTENT WITH DEEP PERITUMORAL INFILTRATION Non-Final OA The Trustees of the University of Pennsylvania
18359502 RAPID SINGLE-CELL MULTIOMICS PROCESSING USING AN EXECUTABLE FILE Final Rejection Illumina, Inc.
18193206 COPY NUMBER VARIANT CALLING FOR LPA KIV-2 REPEAT Non-Final OA Illumina, Inc.
16333933 SOMATIC COPY NUMBER VARIATION DETECTION Final Rejection ILLUMINA, INC.
18429893 METHODS FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS Non-Final OA SEQUENOM, INC.
16235901 MICROSATELLITE INSTABILITY DETECTION Non-Final OA GRAIL, Inc.
17693705 PROGRAMS AND FUNCTIONS IN DNA-BASED DATA STORAGE Final Rejection BIOMEMORY AMERICA, LLC

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month